EA200800963A1 - Egfr-зависимая модуляция экспрессии хемокинов, влияние на терапию и диагностику опухолей и её побочные эффекты - Google Patents

Egfr-зависимая модуляция экспрессии хемокинов, влияние на терапию и диагностику опухолей и её побочные эффекты

Info

Publication number
EA200800963A1
EA200800963A1 EA200800963A EA200800963A EA200800963A1 EA 200800963 A1 EA200800963 A1 EA 200800963A1 EA 200800963 A EA200800963 A EA 200800963A EA 200800963 A EA200800963 A EA 200800963A EA 200800963 A1 EA200800963 A1 EA 200800963A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
tumors
egf receptor
chemokines
egfr
Prior art date
Application number
EA200800963A
Other languages
English (en)
Other versions
EA014433B1 (ru
Inventor
Арне Суттер
Джойс Беренс
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA200800963A1 publication Critical patent/EA200800963A1/ru
Publication of EA014433B1 publication Critical patent/EA014433B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к диагнозу и терапии опухолей, использующих рецептор фактора роста эпидермиса (рецептор EGF), с помощью химических ингибиторов или моноклональных антител. Изобретение относится также к раздражениям кожи, предпочтительно к кожной сыпи, вызванным и связанным с воздействием противораковыми средствами на опухолевые клетки, использующие рецептор EGF. Изобретение направлено также на способы предсказания у пациента эффективности противоопухолевой терапии/реакции опухоли, основанные на применении ингибиторов рецептора EGF, в особенности антител к рецептору EGF. Далее изобретение относится к способу определения оптимальной дозы противоракового средства в терапии опухолей, связанных с рецепторами EGF
EA200800963A 2005-10-11 2006-10-11 Egfr-зависимая модуляция экспрессии хемокинов, влияние на терапию и диагностику опухолей и её побочные эффекты EA014433B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05022127 2005-10-11
PCT/EP2006/009837 WO2007042286A1 (en) 2005-10-11 2006-10-11 Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof

Publications (2)

Publication Number Publication Date
EA200800963A1 true EA200800963A1 (ru) 2008-10-30
EA014433B1 EA014433B1 (ru) 2010-12-30

Family

ID=37460022

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800963A EA014433B1 (ru) 2005-10-11 2006-10-11 Egfr-зависимая модуляция экспрессии хемокинов, влияние на терапию и диагностику опухолей и её побочные эффекты

Country Status (12)

Country Link
US (2) US20080199850A1 (ru)
EP (2) EP2251688A1 (ru)
JP (1) JP2009511524A (ru)
KR (1) KR20080068848A (ru)
CN (1) CN101283275A (ru)
AU (1) AU2006301518B2 (ru)
BR (1) BRPI0617236A2 (ru)
CA (1) CA2625291A1 (ru)
EA (1) EA014433B1 (ru)
IL (1) IL190537A (ru)
WO (1) WO2007042286A1 (ru)
ZA (1) ZA200804006B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US7785632B2 (en) 2003-09-15 2010-08-31 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US9498536B2 (en) * 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) * 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
EP2390361A1 (en) * 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals SA Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IL7R gene
US8498695B2 (en) 2006-12-22 2013-07-30 Novadaq Technologies Inc. Imaging system with a single color image sensor for simultaneous fluorescence and color video endoscopy
US20080269339A1 (en) * 2007-04-26 2008-10-30 Thomas Robert Sutter Combined use of egf pathway inhibitors and differentiation promoting compounds
KR101517264B1 (ko) 2008-03-18 2015-05-04 노바다크 테크놀러지즈 인코포레이티드 결합된 풀-칼라 반사 및 근-적외선 이미지용 이미지 시스템
WO2010148007A2 (en) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
WO2017049237A1 (en) * 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Personalized approach to dosage of anti-fugetactic agent for treatment of cancer
EP4155716A1 (en) 2016-01-26 2023-03-29 Stryker European Operations Limited Image sensor assembly
USD916294S1 (en) 2016-04-28 2021-04-13 Stryker European Operations Limited Illumination and imaging device
CA3026504A1 (en) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with .alpha..nu..beta.3 integrin thyroid antagonists
US10869645B2 (en) 2016-06-14 2020-12-22 Stryker European Operations Limited Methods and systems for adaptive imaging for low light signal enhancement in medical visualization
WO2018145193A1 (en) 2017-02-10 2018-08-16 Novadaq Technologies ULC Open-field handheld fluorescence imaging systems and methods
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
CA3097067A1 (en) 2018-04-16 2019-10-24 Onquality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
JP3854306B2 (ja) 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
EP0839814A3 (en) 1993-05-28 1998-09-16 Cephalon, Inc. Indolocarbazole derivatives and their use for the treatment of prostate gland disorders
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5650407A (en) 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles

Also Published As

Publication number Publication date
CA2625291A1 (en) 2007-04-19
US20080199850A1 (en) 2008-08-21
EP1934599A1 (en) 2008-06-25
CN101283275A (zh) 2008-10-08
AU2006301518A1 (en) 2007-04-19
IL190537A (en) 2011-04-28
US20110244506A1 (en) 2011-10-06
AU2006301518B2 (en) 2012-05-17
IL190537A0 (en) 2008-11-03
EP2251688A1 (en) 2010-11-17
ZA200804006B (en) 2009-03-25
JP2009511524A (ja) 2009-03-19
KR20080068848A (ko) 2008-07-24
EA014433B1 (ru) 2010-12-30
BRPI0617236A2 (pt) 2011-07-19
WO2007042286A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
EA200800963A1 (ru) Egfr-зависимая модуляция экспрессии хемокинов, влияние на терапию и диагностику опухолей и её побочные эффекты
EA201170158A1 (ru) Агенты, связывающиеся с рецептором notch1, и способы их применения
UA94899C2 (ru) Фиксированное дозирование антител к her
EA201170136A1 (ru) Мультимасштабный метод конечных объемов для моделирования резервуара
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
EA200702143A1 (ru) Способы прогнозирования эффективности и лечения рака по увеличенному числу копий гена
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
RU2017126701A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
RU2008152435A (ru) Композиции и способы регулирования развития сосудов
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
JP2008537778A5 (ru)
UA104849C2 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины как ингибиторы киназ janus
MX2009009379A (es) Metodos y composiciones para tratar enfermedades tumorales.
NZ704269A (en) Rspo3 binding agents and uses thereof
EA201071068A1 (ru) Антитела к tyrp1
AU2018239989A8 (en) Methods of measuring signaling pathway activity for selection of therapeutic agents
DE602006011959D1 (de) Na+, k+-atpase-expression bei zervixdysplasie und -krebs
CY1117234T1 (el) Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης
NO20054631L (no) Antistoff mot tumorspesifikt antigen som mal

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU